<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; JAMA</title>
	<atom:link href="http://www.tapanray.in/tag/jama/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Is The Department of Pharmaceuticals On The Same Page As The Prime Minister?</title>
		<link>http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister</link>
		<comments>http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/#comments</comments>
		<pubDate>Sun, 14 May 2017 23:56:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AMC]]></category>
		<category><![CDATA[amended]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[malevolent]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Nexus]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[statute]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unholy]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8225</guid>
		<description><![CDATA[“The open secret is that pharmaceutical companies throw all manners of inducements on doctors to prescribe their medicines. The victim of their misdemeanors is the unsuspecting patient. Mr. Modi clearly wants to break this self-serving chain” – highlighted a media &#8230; <a href="http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Cost-Effective Are New Cancer Drugs?</title>
		<link>http://www.tapanray.in/how-cost-effective-are-new-cancer-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-cost-effective-are-new-cancer-drugs</link>
		<comments>http://www.tapanray.in/how-cost-effective-are-new-cancer-drugs/#comments</comments>
		<pubDate>Mon, 30 Jan 2017 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[anticancer]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Buffet]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[effectiveness]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[malignant]]></category>
		<category><![CDATA[metastatic]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[prolong]]></category>
		<category><![CDATA[rate]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[survival]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[tumors]]></category>
		<category><![CDATA[Warren]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8061</guid>
		<description><![CDATA[The main reason why cancer is so serious a disease, is the ability of the malignant cells to spread in the body, both locally by moving into nearby normal tissue, and regionally to nearby lymph nodes, tissues, or organs, affecting even &#8230; <a href="http://www.tapanray.in/how-cost-effective-are-new-cancer-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-cost-effective-are-new-cancer-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Expensive Is Drug Innovation?</title>
		<link>http://www.tapanray.in/how-expensive-is-drug-innovation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-expensive-is-drug-innovation</link>
		<comments>http://www.tapanray.in/how-expensive-is-drug-innovation/#comments</comments>
		<pubDate>Mon, 16 May 2016 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affairs]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[goods]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Internal]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[REAL]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tufts Centre]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7637</guid>
		<description><![CDATA[High prices for patented drugs are quite often attributed to the exorbitant cost of drug innovation, by the global pharma players. This argument is played, replayed again, again… and again by them, in various ways and forms, especially when many &#8230; <a href="http://www.tapanray.in/how-expensive-is-drug-innovation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-expensive-is-drug-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Marketing Off-label Use of Drugs: A Path Much Abused?</title>
		<link>http://www.tapanray.in/marketing-off-label-use-of-drugs-a-path-much-abused/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=marketing-off-label-use-of-drugs-a-path-much-abused</link>
		<comments>http://www.tapanray.in/marketing-off-label-use-of-drugs-a-path-much-abused/#comments</comments>
		<pubDate>Mon, 30 Nov 2015 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abused]]></category>
		<category><![CDATA[ADE]]></category>
		<category><![CDATA[adverse]]></category>
		<category><![CDATA[cities]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[electronic]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[France]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Internal]]></category>
		<category><![CDATA[Italy]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[methods]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[opposes]]></category>
		<category><![CDATA[path]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[records]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[smart]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[usages]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7296</guid>
		<description><![CDATA[As many would know, prescribing any medicine for disease conditions that are not approved by the drug approving authorities while granting its marketing approval, is generally termed as ‘off-label’ use of drugs. It is also a usual practice in most &#8230; <a href="http://www.tapanray.in/marketing-off-label-use-of-drugs-a-path-much-abused/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/marketing-off-label-use-of-drugs-a-path-much-abused/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unsustainable New Cancer Drug Prices: Resolution Remains A Far Cry</title>
		<link>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry</link>
		<comments>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/#comments</comments>
		<pubDate>Mon, 13 Apr 2015 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[DoP. department of pharmaceuticals]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Far Cry]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[health-economics]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[Marjin]]></category>
		<category><![CDATA[Mayo]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP 2012]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patented Drugs Pricing]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[public health foundation]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 3d]]></category>
		<category><![CDATA[Sloan-Kettering]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[unsustainable]]></category>
		<category><![CDATA[value based pricing]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6530</guid>
		<description><![CDATA[Prices of new drugs for the treatment of life-threatening ailments, such as cancer, are increasingly becoming unsustainable, across the world, and more in India. As articulated by the American Society of Clinical Oncology in 2014, this is primarily due to &#8230; <a href="http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>No More Payment for Prescriptions: Pharma at A Crossroads?</title>
		<link>http://www.tapanray.in/no-more-payment-for-prescriptions-pharma-at-a-crossroads/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=no-more-payment-for-prescriptions-pharma-at-a-crossroads</link>
		<comments>http://www.tapanray.in/no-more-payment-for-prescriptions-pharma-at-a-crossroads/#comments</comments>
		<pubDate>Mon, 23 Dec 2013 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[charitable]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[codes]]></category>
		<category><![CDATA[COI]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[No]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pew]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Rep]]></category>
		<category><![CDATA[rot]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[stem]]></category>
		<category><![CDATA[sunshine act]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unethical]]></category>
		<category><![CDATA[valsatran]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4636</guid>
		<description><![CDATA[“ARE there different and more effective ways of operating than perhaps the ways we as an industry have been operating over the last 30, 40 years?” “TRY and make sure we stay in step with how the world is changing.” &#8230; <a href="http://www.tapanray.in/no-more-payment-for-prescriptions-pharma-at-a-crossroads/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/no-more-payment-for-prescriptions-pharma-at-a-crossroads/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
